Journal of the Korean Association of Oral and Maxillofacial Surgeons

The Korean Association of Oral and Maxillofacial Surgeons (대한구강악안면외과학회)
권호 표지

CHANGE OF THE INVASIVENESS WITH SELECTIVE COX-2 INHIBITION IN AN ORAL SQUAMOUS CELL CARCINOMA CELL LINE, KB ; PRELIMINARY IN VITRO STUDY

선택적 COX-2 저해를 통한 구강암세포주 KB의 침습성 변화에 관한 예비연구

  • Lee, Eun-Jin (Department of Oral & Maxillofacial Surgery, College of Dentistry, Seoul National University Department of Oral Oncology, Institute of Dental Research Seoul National University) ;
  • Kim, Myung-Jin (Department of Oral & Maxillofacial Surgery, College of Dentistry, Seoul National University Department of Oral Oncology, Institute of Dental Research Seoul National University) ;
  • Myoung, Hoon (Department of Oral & Maxillofacial Surgery, College of Dentistry, Seoul National University Department of Oral Oncology, Institute of Dental Research Seoul National University)
  • 이은진 (서울대학교 치과대학 구강악안면외과학교실, 서울대학교 치의학 연구소 구강종양연구부) ;
  • 김명진 (서울대학교 치과대학 구강악안면외과학교실, 서울대학교 치의학 연구소 구강종양연구부) ;
  • 명훈 (서울대학교 치과대학 구강악안면외과학교실, 서울대학교 치의학 연구소 구강종양연구부)
  • Published : 2007.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Cyclooxygenase-2 (Cox-2) is known as one of the critical factor in carcinomas of various organs. However, the importance of Cox-2 in oral squamous cell carcinoma has not been fully described yet. The purpose of this study is to evaluate the anti-cancer effect of selective cox-2 inhibitor, celecoxib in an oral squamous cell carcinoma cell line, KB with respect to cytotoxicity test, in vitro invasion and MMP-2 expression. In cytotoxicity test, celecoxib treated group showed definitely concentration dependent cytotoxicity. In addition, administration of celecoxib reduced the invasive potential of KB cell line significantly in invasion assay. However, there was no remarkable difference of the MMP-2 expression between the celecoxib treated group and the control group. Considering these data, celecoxib had a potential cytotoxic agent to oral squamous cell carcinoma cells. Also, it had anti-invasive property without acting on the MMP-2 expression mechanism. Therefore, it was postulated that celecoxib had the possibility of anti-cancer agent in treatment strategies of oral squamous cell carcinoma.

Keywords

References

  1. Park SW, Lee SG, Song SH, Heo DS, Park BJ, Lee DW, Kim KH, Sung MW: The effect of nitric oxide on cyclooxygenase-2 (COX-2) overexpression in head and neck cancer cell lines. Int J Cancer 2003;107:729-738 https://doi.org/10.1002/ijc.11498
  2. Swamy MV, Cooma I, Patlolla JM, Simi B, Reddy BS, Rao CV: Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: novel strategies for colon cancer prevention and treatment. Mol Cancer Ther 2004;3:215-221
  3. Wei M, Morimura K, Wanibuchi H, Shen J, Doi K, Mitsuhashi M, Moku M, Salim EI, Fukushima S: Chemopreventive effect of JTE- 522, a selective cyclooxygenase-2 inhibitor, on 1, 2-dimethylhydrazine- induced rat colon carcinogenesis. Cancer Lett 2003;202:11- 16 https://doi.org/10.1016/S0304-3835(03)00477-4
  4. Wu J, Xia HH, Tu SP, Fan DM, Lin MC, Kung HF, Lam SK, Wong BC: 15-Lipoxygenase-1 mediates cyclooxygenase-2 inhibitorinduced apoptosis in gastric cancer. Carcinogenesis 2003;24:243-247 https://doi.org/10.1093/carcin/24.2.243
  5. Kawamori T, Uchiya N, Kitamura T, Ohuchida S, Yamamoto H, Maruyama T, Sugimura T, Wakabayashi K: Evaluation of a selective prostaglandin E receptor EP1 antagonist for potential properties in colon carcinogenesis. Anticancer Res 2001;21:3865-3869
  6. Kismet K, Akay MT, Abbasoglu O, Ercan A: Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect Prev 2004;28:127-142 https://doi.org/10.1016/j.cdp.2003.12.005
  7. Kitamura T, Itoh M, Noda T, Matsuura M, Wakabayashi K: Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice. Int J Cancer 2004;109:576-580 https://doi.org/10.1002/ijc.20012
  8. Badawi AF, Eldeen MB, Liu Y, Ross EA, Badr MZ: Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma. Cancer Res 2004;64:1181-1189 https://doi.org/10.1158/0008-5472.CAN-03-2556
  9. Abou-Issa HM, Alshafie GA, Seibert K, Koki AT, Masferrer JL, Harris RE: Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. Anticancer Res 2001;21:3425-3432
  10. Yoshida K, Tanaka T, Kohno H, Sakata K, Kawamori T, Mori H, Wakabayashi K: A COX-2 inhibitor, nimesulide, inhibits chemicallyinduced rat tongue carcinogenesis through suppression of cell proliferation activity and COX-2 and iNOS expression. Histol Histopathol 2003;18:39-48
  11. Furukawa F, Nishikawa A, Lee IS, Kanki K, Umemura T, Okazaki K, Kawamori T, Wakabayashi K, Hirose M: A cyclooxygenase-2 inhibitor, nimesulide, inhibits postinitiation phase of N-nitrosobis(2- oxopropyl)amine-induced pancreatic carcinogenesis in hamsters. Int J Cancer 2003;104:269-273 https://doi.org/10.1002/ijc.10965
  12. Carlton PS, Gopalakrishnan R, Gupta A, Liston BW, Habib S, Morse MA, Stoner GD: Piroxicam is an ineffective inhibitor of N-nitrosomethylbenzylamine- induced tumorigenesis in the rat esophagus. Cancer Res 2002;62:4376-4382
  13. Badawi AF, Badr MZ: Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptorgamma (Review). Int J Oncol 2002;20:1109-1122. Review
  14. Buttar NS, Wang KK, Leontovich O, Westcott JY, Pacifico RJ, Anderson MA, Krishnadath KK, Lutzke LS, Burgart LJ:Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002;122:1101-1112 https://doi.org/10.1053/gast.2002.32371
  15. Ogino S, Kawasaki T, Kirkner GJ, Yamaji T, Loda M, Fuchs CS: Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP. Mod Pathol 2007; 20:15- 22 https://doi.org/10.1038/modpathol.3800709
  16. Soo R, Wu J, Aggarwal A, Tao Q, Hsieh W, Putti T, Tan K, Soon W, Lai Y, Mow B, Hsu S, Loh K, Tan L, Tan P, Goh BC: Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression. Ann Oncol 2006;17:1625-1630 https://doi.org/10.1093/annonc/mdl283
  17. Gately S, Kerbel R: Therapeutic potential of selective cyclooxygenase- 2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res 2003;37:179-192. Review https://doi.org/10.1159/000071373